The Utility and Relevance of Exome Sequence Analysis and Circulating Tumour DNA in Assessing Tumour Heterogeneity in BRAF Mutant Melanoma
Despite recent advances in cancer treatment, little impact has been made on curing as
opposed to controlling cancers over the last several decades. Part of the problem is that
investigators have an incomplete understanding of how tumours behave as they evolve and in
response to treatment. In this trial, the investigators hope to better understand the
evolution of BRAF melanoma in response to drugs a patient may have received such as
vemurafenib or dabrafenib. Importantly, the investigators want to understand how the tumours
evolve resistance to these drugs and whether this can be predicted through blood tests, in
particular of the circulating tumour DNA.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society